186 related articles for article (PubMed ID: 36194200)
1. BMI1 induces ubiquitination and protein degradation of Nod-like receptor family CARD domain containing 5 and suppresses human leukocyte antigen class I expression to induce immune escape in non-small cell lung cancer.
Lu ZH; Tu GJ; Fu SL; Shang K; Peng SJ; Chen L; Gu XJ
Kaohsiung J Med Sci; 2022 Dec; 38(12):1190-1202. PubMed ID: 36194200
[TBL] [Abstract][Full Text] [Related]
2. Eribulin is an immune potentiator in breast cancer that upregulates human leukocyte antigen class I expression via the induction of NOD-like receptor family CARD domain-containing 5.
Wada A; Hirohashi Y; Kutomi G; Murata K; Iwabuchi S; Mizue Y; Murai A; Kyuno D; Shima H; Minowa T; Sasaki K; Kubo T; Kanaseki T; Tsukahara T; Nakatsugawa M; Hashimoto S; Osanai M; Torigoe T; Takemasa I
Cancer Sci; 2023 Dec; 114(12):4511-4520. PubMed ID: 37991442
[TBL] [Abstract][Full Text] [Related]
3. NLRC5 overexpression in ovarian tumors remodels the tumor microenvironment and increases T-cell reactivity toward autologous tumor-associated antigens.
Rodriguez GM; Yakubovich E; Murshed H; Maranda V; Galpin KJC; Cudmore A; Hanna AMR; Macdonald E; Ramesh S; Garson K; Vanderhyden BC
Front Immunol; 2023; 14():1295208. PubMed ID: 38235131
[TBL] [Abstract][Full Text] [Related]
4. NLRC5 Might Promote Endometrial Cancer Progression by Inducing PD-L1 Expression.
Zhu SD; Zhang J; Liu XJ; Zhang JH; Wei B; Wang WY; Fan YJ; Li D; Cao YX; Zhan L
Technol Cancer Res Treat; 2022; 21():15330338221112742. PubMed ID: 35880269
[No Abstract] [Full Text] [Related]
5. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
7. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
8. NLR family CARD domain containing 5 promotes hypoxia-induced cancer progress and carboplatin resistance by activating PI3K/AKT via carcinoembryonic antigen related cell adhesion molecule 1 in non-small cell lung cancer.
Dong Y; Xu T; Li D; Guo H; Du X; Li G; Chen J; Wang B; Wang P; Yu G; Zhao X; Xue R
Bioengineered; 2022 Jun; 13(6):14413-14425. PubMed ID: 36694434
[TBL] [Abstract][Full Text] [Related]
9. NLRC5 deficiency has a moderate impact on immunodominant CD8
Sun T; Ferrero RL; Girardin SE; Gommerman JL; Philpott DJ
Immunol Cell Biol; 2019 Jul; 97(6):552-562. PubMed ID: 30768806
[TBL] [Abstract][Full Text] [Related]
10. Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.
Vijayan S; Sidiq T; Yousuf S; van den Elsen PJ; Kobayashi KS
Immunogenetics; 2019 Mar; 71(3):273-282. PubMed ID: 30706093
[TBL] [Abstract][Full Text] [Related]
11. HLA Class I Antigen Expression in Conjunctival Melanoma Is Not Associated With PD-L1/PD-1 Status.
Cao J; Brouwer NJ; Jordanova ES; Marinkovic M; van Duinen SG; de Waard NE; Ksander BR; Mulder A; Claas FHJ; Heemskerk MHM; Jager MJ
Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):1005-1015. PubMed ID: 29450544
[TBL] [Abstract][Full Text] [Related]
12. Deficiency of the NOD-Like Receptor NLRC5 Results in Decreased CD8
Lupfer CR; Stokes KL; Kuriakose T; Kanneganti TD
J Virol; 2017 Sep; 91(17):. PubMed ID: 28615208
[TBL] [Abstract][Full Text] [Related]
13. Evodiamine suppresses non-small cell lung cancer by elevating CD8
Jiang ZB; Huang JM; Xie YJ; Zhang YZ; Chang C; Lai HL; Wang W; Yao XJ; Fan XX; Wu QB; Xie C; Wang MF; Leung EL
J Exp Clin Cancer Res; 2020 Nov; 39(1):249. PubMed ID: 33208183
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis.
Huang Y; Xia L; Tan X; Zhang J; Zeng W; Tan B; Yu X; Fang W; Yang Z
Cell Mol Biol Lett; 2022 Jun; 27(1):43. PubMed ID: 35658874
[TBL] [Abstract][Full Text] [Related]
15. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.
He Y; Liu S; Mattei J; Bunn PA; Zhou C; Chan D
Drug Des Devel Ther; 2018; 12():981-986. PubMed ID: 29731605
[TBL] [Abstract][Full Text] [Related]
16. HSP27 modulates tumoural immune evasion by enhancing STAT3-mediated upregulation of PD-L1 and NLRC5 in ovarian cancer.
Fezza M; Hilal G; Tahtouh R; Moubarak M; Atallah D
Ecancermedicalscience; 2023; 17():1526. PubMed ID: 37113720
[TBL] [Abstract][Full Text] [Related]
17. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
Wang Y; Sun Q; Mu N; Sun X; Wang Y; Fan S; Su L; Liu X
Cell Commun Signal; 2020 Jul; 18(1):112. PubMed ID: 32665011
[TBL] [Abstract][Full Text] [Related]
18. Expression regulation and function of NLRC5.
Yao Y; Qian Y
Protein Cell; 2013 Mar; 4(3):168-75. PubMed ID: 23483478
[TBL] [Abstract][Full Text] [Related]
19. FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer.
Liu J; Wei L; Hu N; Wang D; Ni J; Zhang S; Liu H; Lv T; Yin J; Ye M; Song Y
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104103
[TBL] [Abstract][Full Text] [Related]
20. NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens.
Yao Y; Wang Y; Chen F; Huang Y; Zhu S; Leng Q; Wang H; Shi Y; Qian Y
Cell Res; 2012 May; 22(5):836-47. PubMed ID: 22491475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
